BioMarin Pharma (BMRN) Tops Q3 EPS by 13c, Revenue Misses

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 9/1/2026

1. SPY
2. MDT
3. SPGI
4. USO
5. AAPL
6. ENOV
7. AON
8. AZN
9. EIX
10. BLSM

October 27, 2016 4:10 PM EDT

BioMarin Pharma (NASDAQ: BMRN) reported Q3 EPS of ($0.26), $0.13 better than the analyst estimate of ($0.39). Revenue for the quarter came in at $279.9 million versus the consensus estimate of $289.44 million.

Updated 2016 Financial Guidance

Revenue Guidance ($ in millions)

Item
Provided August 4, 2016 Updated October 27, 2016
Total BioMarin Revenues $1,100 to $1,150 Unchanged
Vimizim Net Product Revenues $340 to $360 Unchanged
Naglazyme Net Product Revenues $290 to $320 Unchanged
Kuvan Net Product Revenues $340 to $360 Unchanged

Select Income Statement Guidance ($ in millions, except percentages)

Item
Provided August 4, 2016 Updated October 27, 2016
Cost of Sales (% of Total BioMarin Revenues) 18.0% to 19.0% Unchanged
Selling, General and Admin. Expense $470 to $490 $460 to $480
Research and Development Expense $670 to $690 $650 to $670
GAAP Net Loss $(620) to $(650) $(600) to $(630)
non-GAAP Loss $(30) to $(50) $(10) to $(30)

Recent Key Program Updates

For earnings history and earnings-related data on BioMarin Pharma (BMRN) click here.


Serious News for Serious Traders! Try StreetInsider.com Premium Free!

You May Also Be Interested In





Related Categories

Earnings, Guidance

Related Entities

Earnings